Why the study?
P2X4R plays pivotal roles in regulating the cardiovascular system, but therapeutic advances have been hampered by a lack of selective P2X4R agonists.
The P2X4 receptor is a promising therapeutic target for cardiovascular diseases, but clinical translation is currently limited by the lack of selective agonists.
Answers are grounded in this paper and cite their sources.
P2X4R modulation should not yet inform cardiovascular practice; leaves open its therapeutic potential pending selective agonists.
Adenosine triphosphate (ATP) is a primordial versatile autacoid that changes its role from an intracellular energy saver to a signaling molecule once released to the extracellular milieu. Extracellular ATP and its adenosine metabolite are the main activators of the P2 and P1 purinoceptor families, respectively. Mounting evidence suggests that the ionotropic P2X4 receptor (P2X4R) plays pivotal roles in the regulation of the cardiovascular system, yet further therapeutic advances have been hampered by the lack of selective P2X4R agonists. In this review, we provide the state of the art of the P2X4R activity in the cardiovascular system. We also discuss the role of P2X4R activation in kidney and lungs vis a vis their interplay to control cardiovascular functions and dysfunctions, including putative adverse effects emerging from P2X4R activation. Gathering this information may prompt further development of selective P2X4R agonists and its translation to the clinical practice.
No takes yet. Share an insight, caveat, or question.
Bragança et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: